The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
The genome-wide mutational landscape of pituitary adenomas
Open accessAbstract
Pituitary adenomas (PAs) are one of the most common intracranial tumors, which can result in significant morbidity and can cause mortality either by exerting central pressure effects from the pituitary mass or by secreting excessive pituitary hormones 1 . Depending on their capability to produce hormones, PAs are classified as clinically functioning and nonfunctioning (NF). Functioning PAs include 6 subtypes, characterized by hypersecretion of prolactin (PRL), growth hormone (GH), adrenocorticotropin (ACTH), gonadotropins including follicle stimulating hormone and luteinizing hormone (GT), thyrotropin (TSH) or multiple hormones (plurihormonal), respectively. We and other group recently reported the recurrent genetic mutations in ACTH-PAs 2 , 3 . Previous studies also identified genetic alterations in GH-PAs by whole-genome and -exome sequencing 4 , 5 and in 7 NF-PAs by exome analysis 6 . Due to challenges in collection and preparation of PA samples, exome-wide sequencing of other subtypes, including the PRL-, GT-, TSH-, and plurihormonal PA subtypes, has not been reported yet. To provide a comprehensive genetic landscape of all 7 subtypes of PAs, we examined the somatic mutational landscape of 125 PAs, including 20 NF-PAs, 20 PRL-PAs, 20 GH-PAs, 20 ACTH-PAs, 20 GT-PAs, 10 TSH-PAs, and 15 plurihormonal PAs. Plurihormonal PAs in this series secreted GH+PRL ( n = 11), GH+ACTH ( n = 2), or GH+TSH ( n = 2). The analysis of 20 ACTH-PAs included 12 tumor samples analyzed in our previous study 2 . The clinical characteristics of these patients are summarized in Supplementary information, Table S1A . The detailed methods are described in Supplementary information, Data S1 and Figure S1A . We identified 412 somatic mutations in 125 PAs ( Supplementary information, Table S1B ). This analysis confirmed a relatively low number of somatic mutations per tumor across all 7 PA subtypes (mean = 3.3 mutations per exome; Figure 1A ) 3 , 4 , 5 , 6 . The predominant substitution was C>T/G>A transitions which accounted for 41% of all substitutions across all PA subtypes, followed by T>C/A>G transitions (23%), similar to other intracranial tumors ( Supplementary information, Figure S1B ). Figure 1 (A) Somatic mutational and SCNA landscape of PAs. Tumor subtypes based on hormone secretion profile, patient age and gender, mutations in recurrently-mutated genes, number of mutations in each tumor subtype and relative number of different single-nucleotide substitutions in each tumor subtype are shown for 125 PAs. Copy number gain of SYCP1 , SYCP2 , and RAD21L1 , as well as overall percentage of the genome disrupted by copy number variations, are all shown based on GISTIC analysis. (B) Significantly enriched pathways in each subtype based on pathway enrichment analysis. Bipartite network of the association between subtypes and pathways, where a yellow node represents a subtype, a pink node represents a pathway, and the line between these two types of nodes indicates that the pathway was significantly ( P < 0.05) associated with the subtype. Blue lines illustrate associations between a PA subtype and a molecular pathway based on our data in combination with previous whole-exome sequence data. The green lines show the associations between PA subtypes and well-known pathways based on prior publications. (C) Interconnections between each subtype based on pathway analysis. Each pair of subtypes is linked by a line with width corresponding to the number of pathways (containing at least two mutated genes) shared by both subtypes. Node size reflects the number of pathways shared by any other subtypes. (D) The landscape of potential drug targets in 125 PAs. Genes encoding potential drug targets in seven altered pathways are shown. Genes mutated in PAs in this study are shown in ovals. Genes in blue ovals indicate cancer-related genes. Gene names in brown indicate potential drug targets, with their FDA-approved drugs shown in adjacent brown boxes. Orange stars indicate that drugs tested in phases I-III clinical trials are available to target the gene. Full size image Recurrently-mutated genes are shown in Figure 1A . We confirmed mutations in G protein subunit α ( GNAS ), ubiquitin-specific protease 8 ( USP8 ), Nuclear Receptor Subfamily 3 Group C Member 1 ( NR3C1 ), and Menin 1 ( MEN1 ) in PAs and identified new somatic variants in these genes. Activating mutations of GNAS have long been known to play a role in pathogenesis of GH-PAs 7 . In this study, GNAS mutations were identified in 54% of all GH-secreting tumors, including 8 of 20 GH-monosecreting tumors and 11 of 15 plurihormonal tumors that secreted GH and another hormone. The high frequency of GNAS mutations in GH-PAs is consistent with previous findings 4 . GNAS alterations included p.R201C ( n = 14), p.R201H ( n = 1), p.Q227L ( n = 3) and a novel p.G49R ( n = 1) mutation. USP8 is a deubiquitinating enzyme that protects growth factor receptors including EGFR from degradation. Highly freq
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tissue-specific regulation and function of Grb10 during growth and neuronal commitment
Plasschaert, R. N., & Bartolomei, M. S. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411254111 · Cited by 67
Cited by
Pangenomic Classification of Pituitary Neuroendocrine Tumors
Neou, M., Villa, C., Armignacco, R., Jouinot, A., Raffin-Sanson, M.-L., Septier, A., Letourneur, F., Diry, S., Diedisheim, M., Izac, B., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2019.11.002 · Cited by 340
Clinical Biology of the Pituitary Adenoma
Melmed, S., Kaiser, U. B., Lopes, M. B., Bertherat, J., Syro, L. V., Raverot, G., Reincke, M., Johannsson, G., Beckers, A., Fleseriu, M., et al. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac010 · Cited by 321
Metadata
- Authors
- Song, Z.-J., Reitman, Z. J., Ma, Z.-Y., Chen, J.-H., Zhang, Q.-L., Shou, X.-F., Huang, C.-X., Wang, Y.-F., Li, S.-Q., Mao, Y., Zhou, L.-F., Lian, B.-F., Yan, H., Shi, Y.-Y., & Zhao, Y.
- Venue
- Cell Research
- Published
- 2016-09-27
- Volume
- 26
- Issue
- 11
- Pages
- 1255-1259
- ISSN
- 1001-0602 (ISSN-L)
- 1748-7838
- OpenAlex
- W2525902479
- Cited by
- 169
- References
- 1
- FWCI
- 12.99
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.